Research progress on neuroendocrine prostate cancer induced by androgen depriva-tion therapy
10.3969/j.issn.1000-8179.2016.02.205
- VernacularTitle:去势治疗诱导的神经内分泌前列腺癌的研究进展
- Author:
Jun DU
;
Qianqian CHEN
;
Qing YANG
- Publication Type:Journal Article
- Keywords:
prostate cancer;
androgen deprivation therapy;
neuroendocrine differentiation
- From:
Chinese Journal of Clinical Oncology
2016;(2):86-88
- CountryChina
- Language:Chinese
-
Abstract:
Patients with metastatic prostate cancer are typically managed with androgen deprivation therapy. Most patients initially respond to treatment, but many eventually develop castration-resistant prostate cancer. Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of castration-resistant prostate cancer, which often results from neuroendocrine differentiation of prostate cancer cells. NEPC has a dismal outcome with an average survival of less than 1 year and exhibits less response to radiochemotherapy. At least 25%of patients with lethal castration-resistant prostate cancer are predicted to eventually develop this type of highly-aggres-sive NEPC. However, research on the molecular mechanism of NEPC is limited;thus, further studies are needed to explore the develop-ment and application of anticancer drugs for NEPC.
